LivaNova & #039;s Refined Focus Pushes Growth

LivaNova is reinventing itself by shedding off parts that aren’t efficient and tightly focusing on building up its cardiac surgery and neuromodulation businesses. These changes seem to be paying off for the London-based company. Earlier this week, LivaNova said sales for the fourth quarter of 2017 grew 11.5%. For the full year, LivaNova had earnings per share about $3.54, which beat consensus of $3.32. “We were very pleased to exit 2017 with strong momentum and to make the financial commitments that we laid out for you from sales to earnings, LivaNova CEO Damien McDonald said, according to a transcript from Seeking Alpha. “We made significant advancements as the year progressed. Our foundation is solid, and we have an abundance of growth drivers to advance the business.” Worldwide sales from continuing operations for the fourth quarter were $278.4 million, up 8.1 percent on a constant currency basis compared to the fourth quarter of 2016. Don't miss the Advanced Design and Manufacturing Conference and Expo in Cleveland, March 7-8, 2018.   In late 2017, LivaNova began embarking on the mantra of change. The London-based company announced it would divest its cardiac rhythm management (CRM) business to MicroPort for $190 million in cash in November. “We believe this transaction will be favorable for all parties involved,” McDonald said. “For MicroPort, the transaction allows them to strengthen their global presence. For LivaNova, it allows us to focus on our areas...
Source: MDDI - Category: Medical Devices Authors: Tags: Medical Device Business Cardiovascular Source Type: news